May 12, 2016 - Did You Receive a Stryker Hip Broadspire Letter? Prior to the settlement agreement, many patients received a Stryker hip Broadspire letter. Broadspire is a third-party company brought in by Stryker to protect their interests. The Stryker hip Broadspire letter offered some level of compensation to those who were injured by a Rejuvenate or ABGII...

The Stryker Rejuvenate/ABGII Hip Recalls and Subsequent Lawsuits

In July, 2012, Stryker Corporation issued a recall for the Rejuvenate and ABGII hip implants. These devices had been on the market barely more than two years at the time of the recall. When Stryker marketed the implants, they claimed the devices would be perfect for the younger, more active patient. The design of the two Stryker implants was extremely unique, in that there were a variety of stem and neck pieces in different lengths and angles, allowing surgeons to custom-fit the device to the patient according to body size, gender and level of activity. The design also implemented a ceramic, rather than a metal ball, which Stryker claimed made it much safer than other metal-on-metal hip implants, and less likely to shed cobalt and chromium metal ion debris due to Stryker Rejuvenate/ABGII fretting and corrosion. 

The Status of the Stryker Rejuvenate/ABGII Hip Lawsuits

If your are the recipient of a Stryker Rejuvenate/ABGII hip implant, you likely heard of the Stryker Rejuvenate/ABGII hip recalls in July, 2012. Despite the fact that Stryker had marketed both devices as being safer than other metal-on-metal hip implants (due to the use of a ceramic ball) and much longer lasting that most all other hip implants, these claims turned out to be less than accurate. Shortly after the two devices were released in early 2010, adverse event reports began coming in to the FDA. These adverse event reports came from consumers and surgeons alike. In fact, several surgeons notified the FDA that they noted a substance which looked like “black rust” on Stryker Rejuvenate/ABGII hip implants removed from their patients.